Early Phase 1 Myeloma Trial, Recruiting NCT04603872 Sponsor: Zhejiang University Condition: Myeloma
Back to Myeloma

Early Phase 1 Myeloma Trial, Recruiting

NCT04603872
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed (confirmed by lab testing of tissue) with a type of blood cancer that is either a certain type of leukemia (ALL) or lymphoma (NHL) with a specific protein marker called CD19, or a type of blood cancer called multiple myeloma (MM) with a marker called BCMA.
  • Your cancer has come back or has not responded to treatment, meeting at least one of these situations: your cancer never went into remission after standard chemotherapy; remission lasted less than 12 months after your first treatment; one or more follow-up treatments have not worked; your cancer has relapsed two or more times; your cancer came back after a stem cell transplant; or cancer outside the bone marrow has not responded to radiation or chemotherapy.
  • Your liver is functioning well enough, shown by blood test results within acceptable ranges for bilirubin, ALT, and AST (confirm with trial site for exact values).
  • Your kidneys are functioning well enough, shown by a blood test result within an acceptable range for creatinine (confirm with trial site for exact value).
  • A heart scan (echocardiogram) shows your heart is pumping blood effectively enough (at least 50% efficiency).
  • You do not have an active lung infection, and your blood oxygen level in normal indoor air is at least 92%.
  • Your doctor estimates you are likely to live for at least 12 more weeks.
  • You are reasonably able to carry out daily activities, rated on a standard scale from fully active to capable of limited self-care (ECOG score of 0, 1, or 2 — confirm with trial site).
  • If you are a woman who could become pregnant, you tested negative for pregnancy before starting and agree to use effective birth control for at least one year after receiving the treatment.
  • You are willing to take part in the study and sign a consent form.

Who may not be able to join:

  • You have a history of serious brain or neurological conditions, such as head trauma, loss of consciousness, epilepsy/seizures, or bleeding or blockages in the brain.
  • You have a history of serious heart conditions, such as a dangerously abnormal heart rhythm or a prolonged QT interval shown on a heart tracing (ECG).
  • You are currently pregnant or breastfeeding.
  • You have a serious active infection (not including simple urinary tract infections or mild throat infections).
  • You currently have an active hepatitis B or hepatitis C infection.
  • You have been taking steroid medication (taken by mouth or injection throughout the body) within the two weeks before screening, unless you are only using inhaled steroids.
  • You have previously received a CAR-T cell therapy or any other type of genetically modified T cell treatment.
  • Your kidney or liver function test results are above certain levels that suggest these organs are not working well enough (confirm with trial site for exact values).
  • You have other serious health conditions that are not under control and that may make this trial unsuitable for you.
  • You have HIV.
  • The trial doctors believe your situation could put you at increased risk or could affect the reliability of the trial results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 86-13605714822

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Zhejiang University
Registry
ClinicalTrials.gov
Start date
1 November 2020
Est. completion
1 November 2023

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicity (DLT); Incidence of treatment-emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov